Castle Biosciences INC Form 4 insider transactions

Director Rodney Cotton acquired 8,673 Restricted Stock Units in Castle Biosciences, vesting in full on May 23, 2025.

Director Kim Caple acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences, Inc. on May 23, 2024, which will vest on May 23, 2025.

Ellen Goldberg, a director at Castle Biosciences, acquired 8,673 restricted stock units (RSUs) on May 23, 2024, which vest in full on May 23, 2025.

Director Tiffany Olson acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 23, 2024, which vest in full on May 23, 2025.

Director Harrison Miles acquired 8,673 Restricted Stock Units (RSUs) in Castle Biosciences, vesting in full on May 23, 2025.

Director Cole G Bradley acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 23, 2024, which vest in full on May 23, 2025.

Director Daniel Bradbury acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences, Inc. on May 23, 2024, which vest in full on May 23, 2025.

Castle Biosciences CEO Derek Maetzold sold shares of CSTL common stock on May 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Tiffany Olson exercised stock options to acquire 487 shares of Castle Biosciences (CSTL) common stock on May 10, 2024.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on April 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on April 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on April 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Bradbury executed sales of Castle Biosciences (CSTL) common stock on April 4th and 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold sold shares of common stock on April 3, 2024, through a pre-arranged Rule 10b5-1 trading plan.

Director Rodney Cotton acquired 15,988 Restricted Stock Units (RSUs) in Castle Biosciences Inc. on March 26, 2024, which vest in three equal annual installments starting March 26, 2025.

Castle Biosciences CEO Derek Maetzold executed sales of common stock on March 20 and 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences CEO Derek Maetzold sold shares of common stock on March 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, according to a Form 4 filing with the SEC.

Kristen M Oelschlager, COO of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, vesting annually starting March 4, 2025.

Frank Stokes, CFO of Castle Biosciences, acquired 48,744 Restricted Stock Units (RSUs) on March 4, 2024, according to a recent SEC filing.

Castle Biosciences CEO Derek Maetzold reports the acquisition and disposal of company stock, including the vesting of restricted stock units and the exercise of stock options.

Director Daniel Bradbury executed sales of Castle Biosciences (CSTL) common stock on March 4, 2024, under a pre-arranged 10b5-1 trading plan.